
OnKure Therapeutics, Inc.
OKURHealthcare|Biotechnology|US
$2.87
+0.34 (+13.47%)
DCF Value
$4.23
Tangible Book / Share
$3.16
Cash / Share
$3.27
Ownership Breakdown
68.7%
Float
40.5M
Shares Outstanding
27.8M
Float Shares
Major Holders (40)
Combined: 312.6%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Access Industries Holdings LLC | Other | 19.99% | 9,091,532 | Apr 7, 2026 | 13D/G |
| Len Blavatnik | Individual | 19.99% | 9,091,532 | Apr 7, 2026 | 13D/G |
| Access Industries Management, LLC | Other | 19.99% | 9,091,532 | Apr 7, 2026 | 13D/G |
| AI Biotechnology LLC | Other | 19.99% | 9,091,532 | Apr 7, 2026 | 13D/G |
| RA Capital Healthcare Fund, L.P. | Partnership | 9.90% | 4,038,715 | Apr 7, 2026 | 13D/G |
| Rajeev Shah | HC, IN | 9.90% | 4,038,715 | Apr 7, 2026 | 13D/G |
| Peter Kolchinsky | HC, IN | 9.90% | 4,038,715 | Apr 7, 2026 | 13D/G |
| RA Capital Management, L.P. | IA, PN | 9.90% | 4,038,715 | Apr 7, 2026 | 13D/G |
| Anders Hove | Individual | 9.50% | 3,924,037 | Apr 1, 2026 | 13D/G |
| BVF Partners L P/Il | IA, PN | 8.00% | 3,235,778 | Aug 14, 2026 | 13D/G |
| BVF Inc/Il | Corporation | 8.00% | 3,235,778 | Aug 14, 2026 | 13D/G |
| Lampert Mark N | Individual | 8.00% | 3,235,778 | Aug 14, 2026 | 13D/G |
| BVF GP Holdings LLC | Other | 7.30% | 2,961,002 | Aug 14, 2026 | 13D/G |
| Coastlands Capital GP LLC | Other | 6.67% | 2,700,000 | Oct 7, 2026 | 13D/G |
| Coastlands Capital Partners LP | Partnership | 6.67% | 2,700,000 | Oct 7, 2026 | 13D/G |
| Coastlands Capital LP | IA, PN | 6.67% | 2,700,000 | Oct 7, 2026 | 13D/G |
| Matthew D. Perry | HC, IN | 6.67% | 2,700,000 | Oct 7, 2026 | 13D/G |
| Coastlands Capital LLC | HC, OO | 6.67% | 2,700,000 | Oct 7, 2026 | 13D/G |
| StepStone VC MI-G GP, LLC | Other | 6.60% | 2,660,612 | Apr 7, 2026 | 13D/G |
| StepStone Master G, L.P. | Partnership | 6.60% | 2,660,612 | Apr 7, 2026 | 13D/G |
| StepStone Group LP | Partnership | 6.60% | 2,660,612 | Apr 7, 2026 | 13D/G |
| Shay Capital LLC | Other | 6.30% | 810,214 | May 29, 2025 | 13D/G |
| Shay Capital Holdings LLC | Investment adviser | 6.30% | 810,214 | May 29, 2025 | 13D/G |
| Ortav Yehudai | Individual | 6.00% | 2,409,638 | Apr 7, 2026 | 13D/G |
| Trails Edge Biotechnology Master Fund, LP | Partnership | 6.00% | 2,409,638 | Apr 7, 2026 | 13D/G |
| Trails Edge Capital Partners, LP | IA, PN | 6.00% | 2,409,638 | Apr 7, 2026 | 13D/G |
| Daniel Schneeberger | HC, IN | 5.50% | 2,238,684 | Aug 14, 2026 | 13D/G |
| ADAR1 Capital Management, LLC | IA, OO | 5.50% | 2,238,684 | Aug 14, 2026 | 13D/G |
| Cantor Fitzgerald Securities | Partnership | 5.20% | 669,539 | Aug 14, 2025 | 13D/G |
| Cantor Fitzgerald & Co. | Partnership | 5.20% | 669,539 | Aug 14, 2025 | 13D/G |
| Cantor Fitzgerald, L.P. | Partnership | 5.20% | 669,539 | Aug 14, 2025 | 13D/G |
| CF Group Management, Inc. | Corporation | 5.20% | 669,539 | Aug 14, 2025 | 13D/G |
| Acorn Bioventures 2, L.P. | Partnership | 5.00% | 2,069,512 | Apr 1, 2026 | 13D/G |
| Acorn Capital Advisors GP 2, LLC | Other | 5.00% | 2,069,512 | Apr 1, 2026 | 13D/G |
| The Vanguard Group | Investment adviser | 4.87% | 626,593 | Jan 30, 2026 | 13D/G |
| ADAR1 Capital Management GP, LLC | Other | 4.50% | 1,832,117 | Aug 14, 2026 | 13D/G |
| Acorn Capital Advisors GP, LLC | Other | 4.50% | 1,854,525 | Apr 1, 2026 | 13D/G |
| Acorn Bioventures, L.P. | Partnership | 4.50% | 1,854,525 | Apr 1, 2026 | 13D/G |
| Highbridge Capital Management, LLC | IA, OO | 4.20% | 542,361 | Feb 17, 2026 | 13D/G |
| David Kroin | HC, IN | 4.14% | 523,989 | Feb 14, 2025 | 13D/G |
Insider Trades (100)
Last 4 quarters: 2,474,118 acquired · 1,007,644 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Saccomano Nicholas A | director, officer: President and CEO | Sep 21, 2026 | SELL | 87 | $2.97 | $258.76 | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Sep 21, 2026 | SELL | 302 | $2.97 | $898.21 | Form 4 |
| Manke Isaac | Aug 7, 2026 | OTHER | 0 | — | — | Form 4 | |
| Mathers Edward T | director | Aug 7, 2026 | AWARD | 22,350 | $4.14 | $92.5K | Form 4 |
| Ratcliffe Liam | director | Aug 7, 2026 | AWARD | 22,350 | $4.14 | $92.5K | Form 4 |
| Phillips Andrew John | director | Aug 7, 2026 | AWARD | 22,350 | $4.14 | $92.5K | Form 4 |
| Manke Isaac | director | Aug 7, 2026 | AWARD | 300,000 | $4.14 | $1.2M | Form 4 |
| Manke Isaac | director | Aug 7, 2026 | AWARD | 15,300 | $4.14 | $63.3K | Form 4 |
| Manke Isaac | director | Aug 7, 2026 | DISPOSED | 15,300 | $18.20 | $278.5K | Form 4 |
| Jansen Valerie Malyvanh | director | Aug 7, 2026 | AWARD | 22,350 | $4.14 | $92.5K | Form 4 |
| GREY MICHAEL G | director | Aug 7, 2026 | AWARD | 22,350 | $4.14 | $92.5K | Form 4 |
| Carruthers R Michael | director | Aug 7, 2026 | AWARD | 22,350 | $4.14 | $92.5K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | AWARD | 542,232 | $4.14 | $2.2M | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | AWARD | 150,000 | $4.14 | $621.0K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | AWARD | 16,898 | $4.14 | $70.0K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | AWARD | 8,449 | $4.14 | $35.0K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | AWARD | 2,359 | $4.14 | $9.8K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | AWARD | 1,485 | $4.14 | $6.1K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | DISPOSED | 16,898 | $13.99 | $236.4K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | DISPOSED | 542,232 | $18.20 | $9.9M | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Aug 7, 2026 | DISPOSED | 2,359 | $21.20 | $50.0K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Aug 7, 2026 | AWARD | 130,611 | $4.14 | $540.7K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Aug 7, 2026 | AWARD | 50,000 | $4.14 | $207.0K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Aug 7, 2026 | AWARD | 5,781 | $4.14 | $23.9K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Aug 7, 2026 | AWARD | 5,322 | $4.14 | $22.0K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Aug 7, 2026 | DISPOSED | 5,322 | $13.99 | $74.5K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Aug 7, 2026 | DISPOSED | 130,611 | $18.20 | $2.4M | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Aug 7, 2026 | DISPOSED | 5,781 | $21.20 | $122.6K | Form 4 |
| Hartley Dylan | Chief Scientific Officer | Aug 7, 2026 | AWARD | 137,603 | $4.14 | $569.7K | Form 4 |
| Hartley Dylan | Chief Scientific Officer | Aug 7, 2026 | AWARD | 50,000 | $4.14 | $207.0K | Form 4 |
| Hartley Dylan | Chief Scientific Officer | Aug 7, 2026 | DISPOSED | 137,603 | $18.20 | $2.5M | Form 4 |
| Agresta Samuel | Chief Medical Officer | Aug 7, 2026 | AWARD | 131,396 | $4.14 | $544.0K | Form 4 |
| Agresta Samuel | Chief Medical Officer | Aug 7, 2026 | AWARD | 50,000 | $4.14 | $207.0K | Form 4 |
| Agresta Samuel | Chief Medical Officer | Aug 7, 2026 | AWARD | 18,588 | $4.14 | $77.0K | Form 4 |
| Agresta Samuel | Chief Medical Officer | Aug 7, 2026 | DISPOSED | 18,588 | $13.99 | $260.0K | Form 4 |
| Agresta Samuel | Chief Medical Officer | Aug 7, 2026 | DISPOSED | 131,396 | $18.20 | $2.4M | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Jun 22, 2026 | SELL | 86 | $4.40 | $378.08 | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Jun 22, 2026 | SELL | 303 | $4.40 | $1.3K | Form 4 |
| Mathers Edward T | director | Jun 4, 2026 | AWARD | 7,650 | $4.30 | $32.9K | Form 4 |
| Ratcliffe Liam | director | Jun 4, 2026 | AWARD | 1,275 | $4.30 | $5.5K | Form 4 |
| Phillips Andrew John | director | Jun 4, 2026 | AWARD | 7,650 | $4.30 | $32.9K | Form 4 |
| Jansen Valerie Malyvanh | director | Jun 4, 2026 | AWARD | 7,650 | $4.30 | $32.9K | Form 4 |
| GREY MICHAEL G | director | Jun 4, 2026 | AWARD | 7,650 | $4.30 | $32.9K | Form 4 |
| Carruthers R Michael | director | Jun 4, 2026 | AWARD | 7,650 | $4.30 | $32.9K | Form 4 |
| AI Biotechnology LLC | 10 percent owner | Mar 31, 2026 | OTHER | 0 | — | — | Form 4 |
| AI Biotechnology LLC | 10 percent owner | Mar 31, 2026 | OTHER | 5,640,222 | $0.00 | $564.02 | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Apr 1, 2026 | AWARD | 330,000 | $4.07 | $1.3M | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Apr 1, 2026 | AWARD | 110,000 | $4.07 | $447.7K | Form 4 |
| Hartley Dylan | Chief Scientific Officer | Apr 1, 2026 | AWARD | 110,000 | $4.07 | $447.7K | Form 4 |
| Agresta Samuel | Chief Medical Officer | Apr 1, 2026 | AWARD | 110,000 | $4.07 | $447.7K | Form 4 |
| Ratcliffe Liam | director | Mar 31, 2026 | AWARD | 15,300 | $4.14 | $63.3K | Form 4 |
| Ratcliffe Liam | Mar 31, 2026 | OTHER | 0 | — | — | Form 4 | |
| Saccomano Nicholas A | director, officer: President and CEO | Mar 23, 2026 | SELL | 86 | $4.16 | $357.46 | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Mar 23, 2026 | SELL | 301 | $4.16 | $1.3K | Form 4 |
| Mathers Edward T | director | Dec 31, 2025 | AWARD | 3,911 | — | — | Form 4 |
| Manke Isaac | director | Dec 31, 2025 | AWARD | 5,258 | — | — | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Dec 22, 2025 | SELL | 87 | $2.97 | $258.19 | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Dec 22, 2025 | SELL | 302 | $2.97 | $896.25 | Form 4 |
| Mathers Edward T | director | Sep 30, 2025 | AWARD | 4,125 | — | — | Form 4 |
| Manke Isaac | director | Sep 30, 2025 | AWARD | 5,545 | — | — | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Sep 22, 2025 | SELL | 88 | $2.62 | $230.87 | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Sep 22, 2025 | SELL | 303 | $2.62 | $794.92 | Form 4 |
| Mathers Edward T | director | Jun 30, 2025 | AWARD | 4,694 | — | — | Form 4 |
| Manke Isaac | director | Jun 30, 2025 | AWARD | 6,311 | — | — | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Jun 23, 2025 | SELL | 88 | $2.38 | $209.81 | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Jun 23, 2025 | SELL | 303 | $2.38 | $722.41 | Form 4 |
| Mathers Edward T | director | May 28, 2025 | AWARD | 7,650 | $2.44 | $18.7K | Form 4 |
| Phillips Andrew John | director | May 28, 2025 | AWARD | 7,650 | $2.44 | $18.7K | Form 4 |
| Manke Isaac | director | May 28, 2025 | AWARD | 7,650 | $2.44 | $18.7K | Form 4 |
| Jansen Valerie Malyvanh | director | May 28, 2025 | AWARD | 7,650 | $2.44 | $18.7K | Form 4 |
| GREY MICHAEL G | director | May 28, 2025 | AWARD | 7,650 | $2.44 | $18.7K | Form 4 |
| Carruthers R Michael | director | May 28, 2025 | AWARD | 7,650 | $2.44 | $18.7K | Form 4 |
| ACORN BIOVENTURES 2, L.P. | 10 percent owner | May 15, 2025 | OTHER | 0 | — | — | Form 4 |
| Cormorant Asset Management, LP | other: Former 10% Owner | May 15, 2025 | SELL | 1,813,439 | $1.85 | $3.4M | Form 4 |
| ACORN BIOVENTURES, L.P. | 10 percent owner | May 15, 2025 | BUY | 270,270 | $1.85 | $500.0K | Form 4 |
| ACORN BIOVENTURES, L.P. | 10 percent owner | May 15, 2025 | BUY | 1,129,730 | $1.85 | $2.1M | Form 4 |
| Cormorant Asset Management, LP | 10 percent owner | May 12, 2025 | SELL | 24,300 | $1.99 | $48.2K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Apr 4, 2025 | SELL | 358 | $3.33 | $1.2K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Apr 7, 2025 | SELL | 516 | $2.67 | $1.4K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Apr 4, 2025 | SELL | 1,278 | $3.33 | $4.3K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Apr 7, 2025 | SELL | 1,844 | $2.67 | $4.9K | Form 4 |
| Mathers Edward T | director | Mar 31, 2025 | AWARD | 2,580 | — | — | Form 4 |
| Manke Isaac | director | Mar 31, 2025 | AWARD | 3,469 | — | — | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Jan 27, 2025 | AWARD | 130,000 | $5.19 | $674.7K | Form 4 |
| Leverone Jason A. | Chief Financial Officer | Jan 27, 2025 | AWARD | 65,000 | $5.19 | $337.4K | Form 4 |
| Hartley Dylan | Chief Scientific Officer | Jan 27, 2025 | AWARD | 45,000 | $5.19 | $233.6K | Form 4 |
| Agresta Samuel | Chief Medical Officer | Jan 27, 2025 | AWARD | 45,000 | $5.19 | $233.6K | Form 4 |
| Cormorant Asset Management, LP | 10 percent owner | Oct 4, 2024 | OTHER | 0 | — | — | Form 4 |
| ACORN BIOVENTURES, L.P. | 10 percent owner | Oct 4, 2024 | OTHER | 0 | — | — | Form 4 |
| Leonard Braden Michael | other: Former 10% owner of RPHM | Oct 7, 2024 | J | 345,739 | — | — | Form 4 |
| Leonard Braden Michael | other: Former 10% owner of RPHM | Oct 7, 2024 | J | 102,076 | — | — | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Oct 4, 2024 | AWARD | 542,232 | $18.20 | $9.9M | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Oct 4, 2024 | AWARD | 16,898 | $13.99 | $236.4K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Oct 4, 2024 | AWARD | 8,449 | $13.99 | $118.2K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Oct 4, 2024 | AWARD | 4,556 | — | — | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Oct 4, 2024 | AWARD | 2,359 | $21.20 | $50.0K | Form 4 |
| Saccomano Nicholas A | director, officer: President and CEO | Oct 4, 2024 | AWARD | 1,485 | $13.99 | $20.8K | Form 4 |
| Phillips Andrew John | director | Oct 4, 2024 | AWARD | 15,300 | $18.20 | $278.5K | Form 4 |
| Mathers Edward T | director | Oct 4, 2024 | AWARD | 15,300 | $18.20 | $278.5K | Form 4 |
| Manke Isaac | director | Oct 4, 2024 | AWARD | 15,300 | $18.20 | $278.5K | Form 4 |